{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:21:22Z","timestamp":1790990482919,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00417-025-06855-0","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:26:49Z","timestamp":1747193209000},"page":"2349-2358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Time to improvement following teprotumumab treatment of thyroid eye disease: real world experience"],"prefix":"10.1007","volume":"263","author":[{"given":"Yael","family":"Lustig-Barzelay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Yagoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Zunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Hamed-Azzam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbal","family":"Avisar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shay","family":"Kehat-Ophir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Gur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Cukierman-Yaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Agmon-Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphna","family":"Landau-Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy J.","family":"Ben-Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"16","key":"6855_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith TJ, Heged\u00fcs L (2016) Graves\u2019 disease. N Engl J Med 375(16):1552\u20131565","journal-title":"N Engl J Med"},{"issue":"5","key":"6855_CR2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/MED.0000000000000493","volume":"26","author":"GJ Kahaly","year":"2019","unstructured":"Kahaly GJ (2019) Immunotherapies for thyroid eye disease. Curr Opin Endocrinol Diabetes Obes 26(5):250\u2013255","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"11","key":"6855_CR3","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1210\/jc.2013-1804","volume":"98","author":"M Salvi","year":"2013","unstructured":"Salvi M, Vannucchi G, Beck-Peccoz P (2013) Potential utility of rituximab for Graves\u2019 orbitopathy. J Clin Endocrinol Metab 98(11):4291\u20134299","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"6855_CR4","doi-asserted-by":"publisher","first-page":"A842","DOI":"10.1210\/jendso\/bvab048.1718","volume":"5","author":"RS Douglas","year":"2021","unstructured":"Douglas RS, Batten R, Qadeer RA, Cameron C (2021) Meta-analysis of proptosis response in thyroid eye disease: efficacy of EUGOGO recommended treatment regimen with IV methylprednisolone. J Endocr Soc 5(Suppl 1):A842","journal-title":"J Endocr Soc"},{"issue":"4","key":"6855_CR5","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C et al (2021) The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 185(4):G43-67","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"6855_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.beem.2011.11.002","volume":"26","author":"A Eckstein","year":"2012","unstructured":"Eckstein A, Schittkowski M, Esser J (2012) Surgical treatment of Graves\u2019 ophthalmopathy. Best Pract Res Clin Endocrinol Metab 26(3):339\u2013358","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"6855_CR7","doi-asserted-by":"publisher","first-page":"1080204","DOI":"10.3389\/fendo.2022.1080204","volume":"13","author":"J Baeg","year":"2022","unstructured":"Baeg J, Choi HS, Kim C, Kim H, Jang SY (2022) Update on the surgical management of Graves\u2019 orbitopathy. Front Endocrinol 13:1080204","journal-title":"Front Endocrinol"},{"issue":"4","key":"6855_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R et al (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 382(4):341\u201352","journal-title":"N Engl J Med."},{"issue":"6","key":"6855_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/IOP.0000000000001959","volume":"37","author":"SB Diniz","year":"2021","unstructured":"Diniz SB, Cohen LM, Roelofs KA, Rootman DB (2021) Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthal Plast Reconstr Surg 37(6):583\u2013591","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"6855_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101111","volume":"23","author":"CM Sears","year":"2021","unstructured":"Sears CM, Wang Y, Bailey LA, Turbin R, Subramanian PS, Douglas R et al (2021) Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: a multicenter study. Am J Ophthalmol Case Rep 23:101111","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"8","key":"6855_CR11","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","volume":"36","author":"S Ugradar","year":"2022","unstructured":"Ugradar S, Kang J, Kossler AL, Zimmerman E, Braun J, Harrison AR et al (2022) Teprotumumab for the treatment of chronic thyroid eye disease. Eye 36(8):1553\u20131559","journal-title":"Eye"},{"issue":"1","key":"6855_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/clinem\/dgad637","volume":"109","author":"RS Douglas","year":"2024","unstructured":"Douglas RS, Couch S, Wester ST, Fowler BT, Liu CY, Subramanian PS et al (2024) Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab 109(1):25\u201335","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"6855_CR13","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA et al (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376(18):1748\u20131761","journal-title":"N Engl J Med"},{"issue":"5","key":"6855_CR14","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.eprac.2025.01.012","volume":"31","author":"W Huang","year":"2025","unstructured":"Huang W, Ou X, Lin S, Lin W, Chen G, Huang H et al (2025) Efficacy and safety of teprotumumab in thyroid eye disease: a systematic review and meta-analysis. Endocr Pract 31(5):640\u2013649","journal-title":"Endocr Pract"},{"issue":"8","key":"6855_CR15","first-page":"3339","volume":"62","author":"Y Wang","year":"2021","unstructured":"Wang Y, Mester T, Ugradar S, Douglas R (2021) Teprotumumab for the treatment of thyroid eye disease: clinical experience from Expanded Access Program (EAP). Invest Ophthalmol Vis Sci 62(8):3339","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"6855_CR16","first-page":"3327","volume":"62","author":"MO Adetunji","year":"2021","unstructured":"Adetunji MO, Nguyen BJ, Meer E, Kwong B, McGeehan B, Maguire MG et al (2021) Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci 62(8):3327","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"6855_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/bjophthalmol-2020-317806","volume":"106","author":"AP Jain","year":"2022","unstructured":"Jain AP, Gellada N, Ugradar S, Kumar A, Kahaly G, Douglas R (2022) Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. Br J Ophthalmol 106(2):165\u2013171","journal-title":"Br J Ophthalmol"},{"issue":"Suppl 1","key":"6855_CR18","doi-asserted-by":"publisher","first-page":"A861","DOI":"10.1210\/jendso\/bvac150.1781","volume":"6","author":"S Ugradar","year":"2022","unstructured":"Ugradar S, Douglas R (2022) RF35 | PSAT268 reversal of Graves\u2019 disease associated facial volume expansion and eyelid changes following teprotumumab therapy. J Endocr Soc 6(Suppl 1):A861\u2013A862","journal-title":"J Endocr Soc"},{"issue":"9","key":"6855_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000003809","volume":"9","author":"S Ugradar","year":"2021","unstructured":"Ugradar S, Braun J, Wang Y, Zimmerman E, Douglas RS (2021) Facial and eyelid changes in thyroid eye disease are reversed by teprotumumab. Plast Reconstr Surg Glob Open 9(9):e3809","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"6","key":"6855_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/bjophthalmol-2020-318314","volume":"106","author":"S Ugradar","year":"2022","unstructured":"Ugradar S, Wang Y, Mester T, Kahaly GJ, Douglas R (2022) Improvement of asymmetric thyroid eye disease with teprotumumab. Br J Ophthalmol 106(6):755\u2013759","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"6855_CR21","doi-asserted-by":"publisher","first-page":"e654","DOI":"10.1210\/clinem\/dgad213","volume":"108","author":"MN Stan","year":"2023","unstructured":"Stan MN, Krieger CC (2023) The adverse effects profile of teprotumumab. J Clin Endocrinol Metab 108(9):e654\u2013e662","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6855_CR22","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1210\/clinem\/dgac627","volume":"108","author":"L Amarikwa","year":"2023","unstructured":"Amarikwa L, Mohamed A, Kim SH, Kossler AL, Dosiou C (2023) Teprotumumab-related hyperglycemia. J Clin Endocrinol Metab 108(4):858\u2013864","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"6855_CR23","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40618-022-01791-w","volume":"45","author":"L Bartalena","year":"2022","unstructured":"Bartalena L, Marin\u00f2 M, Marcocci C, Tanda ML (2022) Teprotumumab for Graves\u2019 orbitopathy and ototoxicity: moving problems from eyes to ears? J Endocrinol Invest 45(7):1455\u20131457","journal-title":"J Endocrinol Invest"},{"key":"6855_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","volume":"240","author":"CM Sears","year":"2022","unstructured":"Sears CM, Azad AD, Amarikwa L, Pham BH, Men CJ, Kaplan DN et al (2022) Hearing dysfunction after treatment with teprotumumab for thyroid eye disease. Am J Ophthalmol 240:1\u201313","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"6855_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/IOP.0000000000001995","volume":"38","author":"I Belinsky","year":"2022","unstructured":"Belinsky I, Creighton FXJ, Mahoney N, Petris CK, Callahan AB, Campbell AA et al (2022) Teprotumumab and hearing loss: case series and proposal for audiologic monitoring. Ophthal Plast Reconstr Surg 38(1):73","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"6855_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/ohn.955","author":"K Wong","year":"2024","unstructured":"Wong K, Arya P, Salmeron Y, Bigelow DC, Ruckenstein MJ, Banerjee S et al (2024) Patterns of teprotumumab-induced hearing dysfunction: a systematic review. Otolaryngol-Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. https:\/\/doi.org\/10.1002\/ohn.955","journal-title":"Otolaryngol-Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg."},{"issue":"1","key":"6855_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ophtha.2023.08.001","volume":"131","author":"JA Keen","year":"2024","unstructured":"Keen JA, Correa T, Pham C, Claussen AD, Hansen MR, Carter KD et al (2024) Frequency and patterns of hearing dysfunction in patients treated with teprotumumab. Ophthalmology 131(1):30\u201336","journal-title":"Ophthalmology"},{"key":"6855_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101069","volume":"22","author":"MB Safo","year":"2021","unstructured":"Safo MB, Silkiss RZ (2021) A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease. Am J Ophthalmol Case Rep 22:101069","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"2","key":"6855_CR29","first-page":"134","volume":"122","author":"MD Yee","year":"2023","unstructured":"Yee MD, McCarthy J, Quinn B, Surani A (2023) Teprotumumab-induced encephalopathy: a rare side effect of a novel therapeutic. WMJ 122(2):134\u2013137","journal-title":"WMJ"},{"issue":"5","key":"6855_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242153","volume":"14","author":"TD Hoang","year":"2021","unstructured":"Hoang TD, Nguyen NT, Chou E, Shakir MK (2021) Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease. BMJ Case Rep 14(5):e242153","journal-title":"BMJ Case Rep"},{"issue":"1","key":"6855_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12020-024-03852-x","volume":"85","author":"XL Wang","year":"2024","unstructured":"Wang XL, Xu SS, Zhou JB, Song ZH (2024) An observational study on the safety of teprotumumab based on FAERS database. Endocrine 85(1):313\u2013320","journal-title":"Endocrine"},{"issue":"4","key":"6855_CR32","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ophtha.2023.10.018","volume":"131","author":"SA Shah","year":"2024","unstructured":"Shah SA, Amarikwa L, Sears CM, Clauss KD, Rajjoub RD, Kang JY et al (2024) Teprotumumab-related adverse events in thyroid eye disease: a multicenter study. Ophthalmology 131(4):458\u2013467","journal-title":"Ophthalmology"},{"issue":"4","key":"6855_CR33","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-23-0043","volume":"12","author":"P Perros","year":"2023","unstructured":"Perros P, Heged\u00fcs L (2023) Teprotumumab in thyroid eye disease: wonder drug or great divider? Eur Thyroid J 12(4):e230043","journal-title":"Eur Thyroid J"},{"issue":"6","key":"6855_CR34","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0189","volume":"11","author":"HB Burch","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM et al (2022) Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J 11(6):e220189","journal-title":"Eur Thyroid J"},{"issue":"2","key":"6855_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/IOP.0000000000002267","volume":"39","author":"TC Ho","year":"2023","unstructured":"Ho TC, Maamari RN, Kossler AL, Sears CM, Freitag SK, Reshef ER et al (2023) Outcomes of patients with thyroid eye disease partially treated with teprotumumab. Ophthal Plast Reconstr Surg 39(2):150","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"4","key":"6855_CR36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/WNO.0000000000001134","volume":"41","author":"RS Douglas","year":"2021","unstructured":"Douglas RS, Wang Y, Dailey RA, Harris GJ, Wester ST, Schiffman JS et al (2021) Teprotumumab in clinical practice: recommendations and considerations from the OPTIC Trial Investigators. J Neuroophthalmol 41(4):461","journal-title":"J Neuroophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06855-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06855-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06855-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T05:45:21Z","timestamp":1757137521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06855-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6855"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06855-0","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board (IRB), Sheba Medical Center (approval number 4416\u201317-SMC) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patient consent was waived for this anonymized retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support"}},{"value":"The authors have no proprietary or commercial interest in any materials discussed in this article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosure"}}]}}